Increased production of Vyvanse: a strategy to cope with the ADHD medication crisis
Healthcare Response to Drug Shortages – In response to the ongoing challenges faced by patients and healthcare providers in securing adequate supplies of ADHD medications, the Drug Enforcement Administration (DEA) has announced a strategic increase in manufacturing limits for Vyvanse, a leading stimulant medication. This move is intended to alleviate shortages that have affected countless individuals across the nation. This article delves into the details of the DEA’s recent policy adjustment, authorizing a 24 percent increase in the production of lisdexamfetamine, commonly known as Vyvanse. This change is intended to meet growing domestic and international demand for the drug, especially…